Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

STAT reporters discuss why drugmakers have not lobbied against RFK Jr.'s nomination to lead HHS and the struggles around ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

In a report released on December 10, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), ...

Wells Fargo has downgraded Editas Medicine (NASDAQ:EDIT) to equal weight from overweight, citing potential competition for ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...